Phenylalanine and cysteine comprise common miss-sense variants (i.e., single nucleotide polymorphisms [SNPs]) at amino acid position 254 of the human indole(ethyl)amine-N-methyltransferase (hINMT). The phenylalanine variant, which occurs in linkage disequilibrium with two 3’ UTR SNPs, has been reported to associate with elevated urine levels of trimethylselenonium (TMSe), the Se-methylated product of volatile dimethylselenide. hINMT allozymes expressing either cysteine (254C) or phenylalanine (254F) at position 254 were compared for enzyme activity (i.e., K
m
and V
max
) towards the INMT substrates tryptamine, dimethylsulfide (DMS) and dimethylselenide (DMSe)
in vitro
. The SNP 254C had a higher V
max
for DMS and tryptamine in the presence of reducing agent than in its absence. Conversely, V
max
for 254F was insensitive to the presence or absence of reducing agent for these substrates. SNP 254F showed a lower K
m
for tryptamine in the absence of reducing agent than 254C. No statistically significant difference in V
max
or K
m
was observed between 254C and 254F allozymes in the presence of reducing agent for DMSe, The K
m
values for DMSe methylation were about 10-fold (254C) or 6-fold (254F) more favorable than for tryptamine methylation with reducing agent present. These findings indicated that: 1) That phenylalanine at position 254 renders hINMT methylation of substrates DMS and tryptamine insensitive to a non reducing environment. 2) That human INMT harbors significant thioether-S-methyltransferase (TEMT) activity with a higher affinity for DMSe than tryptamine, 3) The reduction of a 44C/254C disulfide bond in hINMT that increases V
max
is proposed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.